This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

开始日期2022-05-17

申办/合作机构

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

[+1]

NCT05225363 / Recruiting临床1期IIT

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells.

开始日期2022-05-05

申办/合作机构

City of Hope National Medical Center

[+1]

ChiCTR2200058969 / Suspended早期临床1期

Phase Ia/Ib, multicenter, open, non-randomized, single-arm clinical trial of humanized different-targeted chimeric antigen receptor T cells in the treatment of relapsed/refractory T-cell lymphoma

开始日期2022-04-21

申办/合作机构-

100 项与 KD-025(Nanjing Kaedi Biotechnology Co Ltd) 相关的临床结果

登录后查看更多信息

100 项与 KD-025(Nanjing Kaedi Biotechnology Co Ltd) 相关的专利（医药）

登录后查看更多信息

项与 KD-025(Nanjing Kaedi Biotechnology Co Ltd) 相关的文献（医药）

2023-08-14·Experimental hematology & oncology

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.

Review

作者: Tingxun Lu ; Jie Zhang ; Zijun Y Xu-Monette ; Ken H Young

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30-40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT). However, the patients who failed in salvage treatment or those ineligible for subsequent auto-SCT have dismal outcomes. Several immune-based therapies have been developed, including monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engaging antibodies, chimeric antigen receptor T-cells, immune checkpoint inhibitors, and novel small molecules. Meanwhile, allogeneic SCT and radiotherapy are still necessary for disease control for fit patients with certain conditions. In this review, to expand clinical treatment options, we summarize the recent progress of immune-related therapies and prospect the future indirections in patients with R/R DLBCL.

2023-07-06·International journal of molecular sciences

Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.

Review

作者: Yoshiaki Yura ; Masakazu Hamada

Sjögren's syndrome (SS) is an autoimmune disease characterized by the involvement of exocrine glands such as the salivary and lacrimal glands. The minor salivary glands, from which tissue samples may be obtained, are important for the diagnosis, evaluation of therapeutic efficacy, and genetic analyses of SS. In the onset of SS, autoantigens derived from the salivary glands are recognized by antigen-presenting dendritic cells, leading to the activation of T and B cells, cytokine production, autoantibody production by plasma cells, the formation of ectopic germinal centers, and the destruction of salivary gland epithelial cells. A recent therapeutic approach with immune checkpoint inhibitors for malignant tumors enhances the anti-tumor activity of cytotoxic effector T cells, but also induces SS-like autoimmune disease as an adverse event. In the treatment of xerostomia, muscarinic agonists and salivary gland duct cleansing procedure, as well as sialendoscopy, are expected to ameliorate symptoms. Clinical trials on biological therapy to attenuate the hyperresponsiveness of B cells in SS patients with systemic organ involvement have progressed. The efficacy of treatment with mesenchymal stem cells and chimeric antigen receptor T cells for SS has also been investigated. In this review, we will provide an overview of the pathogenesis of salivary gland lesions and recent trends in therapeutic approaches for SS.

2023-07-03·Journal of cancer research and clinical oncology

Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.

Article

作者: Yeye Zhou ; Bin Zhang ; Jiangqin Han ; Na Dai ; Tongtong Jia ; Haiwen Huang ; Shengming Deng ; Shibiao Sang

BACKGROUND:

In our current work, an ¹⁸F-FDG PET/CT radiomics-based model was developed to assess the progression-free survival (PFS) and overall survival (OS) of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR)-T cell therapy.

METHODS:

A total of 61 DLBCL cases receiving ¹⁸F-FDG PET/CT before CAR-T cell infusion were included in the current analysis, and these patients were randomly assigned to a training cohort (n = 42) and a validation cohort (n = 19). Radiomic features from PET and CT images were obtained using LIFEx software, and radiomics signatures (R-signatures) were then constructed by choosing the optimal parameters according to their PFS and OS. Subsequently, the radiomics model and clinical model were constructed and validated.

RESULTS:

The radiomics model that integrated R-signatures and clinical risk factors showed superior prognostic performance compared with the clinical models in terms of both PFS (C-index: 0.710 vs. 0.716; AUC: 0.776 vs. 0.712) and OS (C-index: 0.780 vs. 0.762; AUC: 0.828 vs. 0.728). For validation, the C-index of the two approaches was 0.640 vs. 0.619 and 0.676 vs. 0.699 for predicting PFS and OS, respectively. Moreover, the AUC was 0.886 vs. 0.635 and 0.778 vs. 0.705, respectively. The calibration curves indicated good agreement, and the decision curve analysis suggested that the net benefit of radiomics models was higher than that of clinical models.

CONCLUSIONS:

PET/CT-derived R-signature could be a potential prognostic biomarker for R/R DLBCL patients undergoing CAR-T cell therapy. Moreover, the risk stratification could be further enhanced when the PET/CT-derived R-signature was combined with clinical factors.

项与 KD-025(Nanjing Kaedi Biotechnology Co Ltd) 相关的新闻（医药）

2023-08-03

·医药观澜

刚刚！ROCK2抑制剂「贝舒地尔」在中国获批上市

▎药明康德内容团队报道今日（8月3日），中国国家药品监督管理局（NMPA）官网最新公示，烨辉医药申报的ROCK2抑制剂甲磺酸贝舒地尔片上市申请已获得批准。根据烨辉医药此前发布的新闻稿，该药本次在中国获批用于治疗慢性移植物抗宿主病（cGVHD）。值得一提的是，贝舒地尔（belumosudil）已于2021年在美国获批治疗12岁以上的cGVHD患者，是首款获FDA批准的ROCK2抑制剂。截图来源：NMPA官网造血干细胞移植是治疗血液或骨髓癌症的常见手段。然而，在cGVHD患者中，移植的免疫细胞会攻击宿主的健康细胞，从而带来一系列严重的副作用。据估计，大约有30%-70%接受造血干细胞移植的患者会出现cGVHD症状，包括炎症反应和多器官组织纤维化。Belumosudil是由Kadmon Holdings公司开发的一款ROCK2激酶抑制剂，ROCK2介导的信号通路在调节炎症和纤维化反应中具有重要作用。Belumosudil能通过减轻STAT3的磷酸化，加强STAT5的磷酸化，从而下调过度活化的T辅助细胞（Th17），并增强调节性T细胞（Treg）功能，进而重建免疫平衡。▲Belumosudil作用机制图示（图片来源：参考资料[4]）2019年，烨辉医药与Kadmon Holdings达成战略合作，成立合资公司BK Pharmaceuticals在中国开发和商业化belumosudil用于治疗GVHD。值得一提的是，2021年9月，Kadmon Holdings已被赛诺菲（Sanofi）以约19亿美元收购。由于治疗效果显著，belumosudil曾被FDA授予突破性疗法认定、孤儿药资格和优先审评资格，用于治疗cGVHD患者。2020年，NMPA也将belumosudil纳入突破性治疗品种，拟用于至少经过一线系统治疗的慢性移植物抗宿主病患者的治疗。2021年7月，FDA批准belumosudil用于治疗12岁以上的慢性移植物抗宿主病患者，这些患者曾接受过两种前期全身性治疗。Belumosudil的治疗效果已在一项名为ROCKstar的随机、开放标签、多中心关键性临床试验中得到了验证。在该研究中，共计有65名患者接受了belumosudil的治疗。试验结果显示：belumosudil治疗组患者的总缓解率（ORR）为75%，完全缓解率为6％；出现首次缓解所需的中位时间为1.8个月，62%获得缓解的患者在缓解后至少12个月不需要使用新的全身性疗法，中位缓解持续时间为1.9个月。参考资料：[1]2023年08月03日药品批准证明文件送达信息发布. Retrieved Aug 3 ，2023, from https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230803153813176.html[2]烨辉医药宣布在中国提交Belumosudil治疗慢性移植物抗宿主病的新药申请(NDA). Retrieved Nov. 24，2021, from https://mp.weixin.qq.com/s/qiOtDcFY8nKyLXz_43LbUA[3] FDA approves belumosudil for chronic graft-versus-host disease. Retrieved July 16, 2021, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belumosudil-chronic-graft-versus-host-disease[4] Kadmon Holdings公司官网 . From https://kadmon.com/clinical-pipeline/pipeline/#about-kd025本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

突破性疗法孤儿药优先审批上市批准并购

2023-07-04

·美通社

博腾生物与凯地医疗深化战略合作，共同推进细胞治疗药物全球化开发

苏州 2023年7月4日 /美通社/ -- 2023年6月30日，苏州博腾生物制药有限公司（简称博腾生物）与南京凯地医疗技术有限公司（简称凯地医疗）举行战略合作签约仪式，深化细胞治疗药物的研发与生产合作，共同推进新药在中国、美国乃至全球市场的开发。博腾生物与凯地医疗深化战略合作，共同推进细胞治疗药物全球化开发今年3月，凯地医疗自主研发的实体瘤CAR-T项目KD-025细胞注射液，临床试验申请（IND）通过国家药品监督管理局药品审评中心（CDE）默许。博腾生物作为独家CDMO合作伙伴，为该项目提供了CMC研究开发服务，包括质粒、病毒、CAR-T细胞的工艺开发、生产及CMC部分的IND注册申报支持等服务。博腾生物拥有端到端的基因与细胞治疗CDMO服务平台，覆盖质粒、细胞治疗、基因治疗、溶瘤病毒、核酸治疗及活菌疗法等领域。此次签约将进一步强化双方的战略合作，在现有的合作基础上，拓展细胞治疗药物的美国IND申报、临床以及商业化生产，加快药物在全球范围内的研发进程。博腾生物与凯地医疗深化战略合作，共同推进细胞治疗药物全球化开发凯地医疗创始人、执行总裁兼董事长代红久博士表示：“非常高兴与博腾生物全面强化战略合作关系，凯地医疗开发了多条细胞治疗新药研发管线，今年也获批了国内首个靶向NKG2DL的细胞治疗产品，我们相信凭借博腾生物专业的团队和平台，可以帮助凯地医疗实现细胞治疗药物在美国乃至全球的IND申报和商业化进程。” 博腾生物营销部副总经理阎宇表示：“非常感谢凯地医疗对博腾生物的信任和支持，很荣幸我们能够支持凯地医疗实体瘤CAR-T项目在中国的IND申报，博腾生物拥有专业团队和丰富的项目经验，可支持基因与细胞治疗药物的国际申报，相信能够助力凯地医疗新药研发在全球的突破，让好药更早惠及大众。” 关于凯地医疗凯地医疗是一家处于临床阶段的新药研发公司，公司致力于利用领先合成生物学技术平台开发实体肿瘤患者临床未满足需求的新型细胞药物。依托公司自主CAR文库筛选平台—KD-SmCAR™及双靶向CAR开发平台—KD-ScCAR™，凯地医疗已成功开发多条针对实体肿瘤的细胞新药管线，含下一代自体及异体CAR-T/CAR-NK等管线。目前已申报CAR相关中美专利30余件，获授权专利15件，其中核心管线KD-025、KD-496等专利均为中美首次授权。靶向NKG2DL适应症为肝癌、结直肠癌及胶质瘤的KD-025 CAR-T产品开发成果先后在国际肿瘤免疫治疗权威杂志《Journal for ImmunoTherapy of Cancer》和《Cancer Immunology Research》及美国肿瘤临床年会ASCO发表。早前在国内知名临床中心开展的KD-025 CAR-T IIT临床试验，已完成多例低剂量给药，无明显毒副反应，产品安全有效，为国内首个靶向NKG2DL实体瘤 CAR-T (KD-025)细胞注射液 IND 申请获CDE临床批件公司，目前正在与多家合作单位协商启动KD-025注册一期临床，以此同时，公司核心产品KD-496作为全球首个新型双靶向CAR-T细胞注射液进入IIT临床阶段。此外，凯地医疗正在推进下一代异体通用CAR-T/CAR-NK等布局，有望在不久将来将凯地医疗打造成实体瘤细胞治疗全球知名企业。公司已建成3000平方米GMP细胞药物研发与生产中心，并完成近亿元融资，正在进行B轮融资；与此同时，公司正在以战略合作方式快速推进合成生物学产品的开发与商业化。关于博腾生物苏州博腾生物制药有限公司成立于 2018 年 12 月，立足于苏州工业园区，以上市公司 - 重庆博腾制药科技股份有限公司（股票代码： 300363 ）为依托，搭建了质粒，病毒载体和细胞治疗产品为一体的 CDMO 平台，提供从早期研究、研究者发起的临床、新药临床试验申请（ IND ）、注册临床试验样品和商业化生产服务，加快药物研究转化进程。博腾生物聚焦基因与细胞治疗，在博腾股份的成功经验之上，以国际一流的专业人才为核心，秉承 “ 客户第一 ” 的服务宗旨，以 “ 合规、专业、专注、开放协作 ” 为品牌理念，延续母公司强大的 IP 保护和项目管理机制以及完善的质量管理体系，充分利用核心团队将基因和细胞治疗产品推向临床直至上市的成功经验，为全球客户提供优质和高效的服务，让好药更早惠及大众。

临床申请细胞疗法免疫疗法

2023-05-25

·PRNewswire

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The prevalence of idiopathic pulmonary fibrosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of idiopathic pulmonary fibrosis and the growing research and development activities to develop novel therapies to treat idiopathic pulmonary fibrosis to drive the market. The companies developing the potential therapies in the last stage of development include FibroGen, Boehringer Ingelheim, and several others. LAS VEGAS, May 25, 2023 /PRNewswire/ -- DelveInsight's ' Idiopathic Pulmonary Fibrosis Pipeline Insight – 2023 ' report provides comprehensive global coverage of pipeline idiopathic pulmonary fibrosis therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the idiopathic pulmonary fibrosis pipeline domain. Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report DelveInsight's idiopathic pulmonary fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for idiopathic pulmonary fibrosis treatment. Key idiopathic pulmonary fibrosis companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others are evaluating new idiopathic pulmonary fibrosis drugs to improve the treatment landscape. Promising idiopathic pulmonary fibrosis pipeline therapies in various stages of development include Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others. In May 2023, Kinarus Therapeutics announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China ("CDIM"). Further, this agreement forms the basis for discussions on the introduction, development and commercialization of KIN001 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, introduced CDIM to Kinarus. In April 2023, AGC Biologics announced it signed a service agreement with The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan. In February 2023, Insilico Medicine announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). In February 2023, Arrowhead Pharmaceuticals Inc. announced that it had dosed the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF). In February 2023, South Korea's Daewoong Pharmaceutical secured an exclusive licensing agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in the Greater China region, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license Bersiporocin for Idiopathic Pulmonary Fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to $336 million, including up to $76 million in upfront and development milestone payments and double-digit royalties on Net Sales. In January 2023, Insilico Medicine announced the positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase 1 clinical trial of INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF). In January 2023, Pliant Therapeutics announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). In December 2022, Vallon Pharmaceuticals announced that they entered into a definitive agreement (the "Merger Agreement") pursuant to which GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Following the closing of the Merger, the combined company is expected to operate under the name "GRI Bio, Inc." Request a sample and discover the recent advances in idiopathic pulmonary fibrosis drug treatment @ Idiopathic Pulmonary Fibrosis Pipeline Report The idiopathic pulmonary fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage idiopathic pulmonary fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the idiopathic pulmonary fibrosis clinical trial landscape. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that primarily affects middle-aged and older adults. It affects lung tissue by thickening, stiffening, or persistent and progressive scarring that worsens irreversibly over time. Scarring affects the air sacs of IPF patients, decreasing the amount of oxygen that enters the circulation. With less oxygen in the blood, ordinary tasks such as walking can cause dyspnea. This set of lung illnesses is also known as 'Diffuse Parenchymal Lung Diseases,' and it is distinguished by a broader umbrella of 'Interstitial Lung Diseases (IDLs)'. The cause of IPF is uncertain; experts believe the condition is caused by a mix of hereditary and environmental factors. There is a significant chance that genetic variations enhance a person's risk of acquiring IPF and then being exposed to environmental variables that aggravate the condition. However, much remains unknown about this new field of study. Find out more about drugs for idiopathic pulmonary fibrosis @ New Idiopathic Pulmonary Fibrosis Drugs A snapshot of the Idiopathic Pulmonary Fibrosis Pipeline Drugs mentioned in the report: Learn more about the emerging idiopathic pulmonary fibrosis pipeline therapies @ Idiopathic Pulmonary Fibrosis Clinical Trials Idiopathic Pulmonary Fibrosis Therapeutics Assessment The idiopathic pulmonary fibrosis pipeline report proffers an integral view of idiopathic pulmonary fibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report Coverage: Global Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Mechanism of Action: Connective tissue growth factor inhibitors, 5-lipoxygenase inhibitors, Leukotriene D4 receptor antagonists, Leukotriene receptor antagonists, Phospholipase C inhibitors, Thromboxane A2 receptor antagonists, Type 3 cyclic nucleotide phosphodiesterase inhibitors, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Integrin alphavbeta1 inhibitors, Integrin alphaVbeta6 inhibitors, Antibody-dependent cell cytotoxicity, Interleukin 4 receptor antagonists, SMO protein inhibitors, Galectin 3 inhibitors Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others. Key Idiopathic Pulmonary Fibrosis Pipeline Therapies: Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others. Dive deep into rich insights for new drugs for idiopathic pulmonary fibrosis treatment; visit @ Idiopathic Pulmonary Fibrosis Medications Table of Contents For further information on the idiopathic pulmonary fibrosis pipeline therapeutics, reach out @ Idiopathic Pulmonary Fibrosis Drug Treatment Related Reports Idiopathic Pulmonary Fibrosis Market Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key idiopathic pulmonary fibrosis companies, including FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLC, among others. Idiopathic Pulmonary Fibrosis Epidemiology Forecast Idiopathic Pulmonary Fibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic pulmonary fibrosis epidemiology trends. Pulmonary Fibrosis Pipeline Pulmonary Fibrosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary fibrosis companies, including Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others. Pulmonary Fibrosis Market Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary fibrosis companies, including Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床1期引进/卖出孤儿药临床2期

100 项与 KD-025(Nanjing Kaedi Biotechnology Co Ltd) 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
胶质母细胞瘤	临床2期	中国更多	南京凯地生物科技有限公司更多
髓母细胞瘤	临床1期	中国更多	南京凯地生物科技有限公司更多
结肠癌	临床1期	中国更多	南京凯地生物科技有限公司更多
肝细胞癌	临床1期	中国更多	南京凯地生物科技有限公司更多
NKG2DL阳性实体瘤	临床申请批准	中国更多	南京凯地生物科技有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


KD025-208 (EHA2019) AI 标引	临床2期	慢性移植物抗宿主病	54	KD025 200 mg QD	顧夢夢衊選願積網網鹹(鹽憲夢鏇鹹簾襯製範憲) = Commonly reported AEs were URTI, AST/ALT elevations, fatigue, nausea and diarrhea. 憲鏇鏇夢遞獵壓憲鹹範 (遞網鑰窪積觸獵廠獵築 ) 更多	积极	2019-06-15
				KD025 200 mg BID
NCT02924753 (ASCO2018) 人工标引	临床1期	B细胞慢性淋巴细胞白血病	29	chimeric antigen receptor T cells (ALL)	遞簾築憲範窪鏇築壓製(夢積鹽鹽膚鹹選製艱蓋) = 淵鏇襯餘餘鏇淵簾鏇壓齋鹽構餘網糧壓夢膚顧 (鏇淵願蓋蓋鹽齋膚選鏇 ) 更多	积极	2018-06-04
				chimeric antigen receptor T cells (B-cell lymphoma)	遞簾築憲範窪鏇築壓製(夢積鹽鹽膚鹹選製艱蓋) = 齋鏇築範願鏇壓膚顧壓齋鹽構餘網糧壓夢膚顧 (鏇淵願蓋蓋鹽齋膚選鏇 ) 更多
NCT02317627 (CTgov)	临床2期	寻常性银屑病	38	KD025 (400 mg QD)	(願壓繭廠製蓋範齋廠鑰) = 選鬱淵夢鹽網積蓋壓構製淵蓋構觸廠繭積選積 (鏇網積網簾憲獵襯鑰顧, 網齋鑰鹽鬱蓋鹹願積蓋 ~ 積積廠願鏇製蓋範製糧) 更多	-	2021-11-01
				KD025 (200 mg BID)	(願壓繭廠製蓋範齋廠鑰) = 願衊夢網衊衊廠選憲遞製淵蓋構觸廠繭積選積 (鏇網積網簾憲獵襯鑰顧, 窪襯鏇網鑰繭窪壓願遞 ~ 壓範齋選鬱淵襯糧醖遞) 更多